Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.

From today, the updated indication for TRIKAFTA is as follows: TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in ...

A big part of why Prince-Saxon was even able to take on this feat is the drug Trikafta, which received public funding through Pharmac in April 2023 for people with CF aged six and over.

Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio. GlobalData provides trusted ...

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...

The patients of cystic fibrosis (CF), their families, and public health experts are pinning their hopes on the expected outcome from the Karnataka High Court regarding availability of affordable ...